Eli Lilly and Company $LLY Shares Sold by GAMMA Investing LLC

GAMMA Investing LLC reduced its position in Eli Lilly and Company (NYSE:LLY) by 4.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,180 shares of the company’s stock after selling 804 shares during the quarter. Eli Lilly and Company makes up approximately 0.7% of GAMMA Investing LLC’s portfolio, making the stock its 18th biggest position. GAMMA Investing LLC’s holdings in Eli Lilly and Company were worth $13,108,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Trust Co of the South grew its holdings in shares of Eli Lilly and Company by 21.3% in the third quarter. Trust Co of the South now owns 1,086 shares of the company’s stock valued at $829,000 after purchasing an additional 191 shares in the last quarter. Capital Asset Advisory Services LLC grew its stake in shares of Eli Lilly and Company by 5.2% in the third quarter. Capital Asset Advisory Services LLC now owns 6,430 shares of the company’s stock worth $4,906,000 after acquiring an additional 315 shares in the last quarter. Jacobs & Co. CA increased its position in shares of Eli Lilly and Company by 2.5% during the third quarter. Jacobs & Co. CA now owns 31,360 shares of the company’s stock worth $23,928,000 after acquiring an additional 755 shares during the period. Roxbury Financial LLC raised its stake in shares of Eli Lilly and Company by 28.3% in the third quarter. Roxbury Financial LLC now owns 240 shares of the company’s stock valued at $183,000 after acquiring an additional 53 shares in the last quarter. Finally, Farmers Trust Co. raised its stake in shares of Eli Lilly and Company by 25.8% in the third quarter. Farmers Trust Co. now owns 614 shares of the company’s stock valued at $468,000 after acquiring an additional 126 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

LLY stock opened at $1,062.67 on Tuesday. The business has a 50 day moving average price of $943.82 and a 200 day moving average price of $822.76. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The stock has a market cap of $1.00 trillion, a price-to-earnings ratio of 51.99, a PEG ratio of 1.14 and a beta of 0.37. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm’s revenue was up 53.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.7%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on LLY shares. BMO Capital Markets set a $1,200.00 target price on Eli Lilly and Company in a research note on Thursday, December 4th. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Bank of America cut their target price on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a research note on Monday. Guggenheim reaffirmed a “buy” rating and issued a $1,163.00 target price on shares of Eli Lilly and Company in a report on Wednesday, December 3rd. Finally, UBS Group boosted their price target on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,128.55.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.